ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021
Circulating Tumor DNA Analysis Detects
Open access · hybridAbstract readCase Reports
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
3.2field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 59 citations in OpenAlex.
- FGFR2 amplification and fusion identified by NGS align with FGFR2b overexpression.Virchows Archiv : an international journal of pathology · 2026Article
- Circulating Tumor DNA Sequencing for Early Diagnosis and Detection of Treatment Response, Minimal Residual Disease, and Recurrence in Gastroesophageal Cancer.Journal of gastrointestinal cancer · 2026Review
- Integrative multi-omics and single-cell analysis identifies EGFR pathway activation and metabolic reprogramming as potential synthetic lethal vulnerabilities in resistance to the FGFR inhibitor AZD4547.Journal of translational medicine · 2026Article
- Review
- Article
- Targeted therapies for urothelial carcinoma: From FGFR inhibitors to next‑generation antibody-drug conjugates (Review).International journal of oncology · 2026Review
- Emerging liquid biopsy markers in thyroid cancer: from isolation technologies to clinical translation.Frontiers in endocrinology · 2026Review
- Nanotechnology-Assisted Molecular Profiling: Emerging Advances in Circulating Tumor DNA Detection.International journal of nanomedicine · 2026Review
- Design and synthesis of an erdafitinib-based selective FGFR2 degrader.Beilstein journal of organic chemistry · 2026Article
- From Tumor Biology to Clinical Perspectives: Novel Biomarkers and Therapeutic Insights in Gastric Cancer.Oncology research · 2026Review
- Cross-Cancer Detectability of ctDNA Biomarkers in Asian Populations: Implications for Pan-Cancer Detection.Cancer management and research · 2026Review
- Bibliometric analysis of global research on liquid biopsy for gastric cancer.Discover oncology · 2025Article
- Circulating Tumor DNA (ctDNA) in Gastroesophageal Adenocarcinoma (GEA): Evidence and Emerging Applications.Cancers · 2025Review
- The Role of FGFR2 as a Novel Biomarker for Treatment of Gastric Cancer-A Literature Review.Medicina (Kaunas, Lithuania) · 2025Review
- FGFR1-amplified colorectal cancer: a distinct prognostic subtype identified through integrated genomic and immunohistochemical profiling.ESMO open · 2025Article
- Circulating tumor DNA predicts clinical benefits of immune checkpoint blockade in HER2-negative patients with advanced gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025Article
- WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD).ESMO gastrointestinal oncology · 2025Article
- Role of circulating tumor DNA methylation in gastric cancer initiation and progression: A comprehensive review.World journal of gastrointestinal oncology · 2025Review
- Clinical Significance of Extrachromosomal DNA inJCO precision oncology · 2025Article
- Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study.JCO precision oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 20 institutions in 2 countries.
Tomoko JogoDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
Yoshiaki NakamuraDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan. yoshinak@east.ncc.go.jp.
Kohei ShitaraDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
Hideaki BandoDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan.ORCID 0000-0001-5041-2765
Hisateru YasuiDepartment of Medical Oncology, Kobe City Medical Center General Hospital, Hyogo, Japan.
Taito EsakiDepartment of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Tetsuji TerazawaCancer Chemotherapy Center, Osaka Medical College Hospital, Osaka, Japan.
Taroh SatohDepartment of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, Osaka, Japan.ORCID 0000-0002-4615-2638
Eiji ShinozakiDepartment of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Tomohiro NishinaDepartment of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan.
Yu SunakawaDepartment of Clinical Oncology, St. Marianna University School of Medicine, Kanagawa, Japan.ORCID 0000-0002-0163-7543
Yoshito KomatsuDepartment of Cancer Center, Hokkaido University Hospital, Hokkaido, Japan.ORCID 0000-0002-1570-6802
Hiroki HaraDepartment of Gastroenterology, Saitama Cancer Center, Saitama, Japan.
Eiji OkiDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID 0000-0002-9763-9366
Nobuhisa MatsuhashiDepartment of Surgical Oncology, Graduate School of Medicine, Gifu University, Gifu, Japan.
Takashi OhtaDepartment of Clinical Oncology, Kansai Rosai Hospital, Hyogo, Japan.ORCID 0000-0002-1941-206X
Takeshi KatoDepartment of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan.ORCID 0000-0001-5347-550X
Koushiro OhtsuboDivision of Medical Oncology, Cancer Research Institute, Kanazawa University, Ishikawa, Japan.ORCID 0000-0002-4490-4306
Takeshi KawakamiDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Naohiro OkanoDepartment of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan.
Yoshiyuki YamamotoDepartment of Gastroenterology, University of Tsukuba Hospital, Ibaraki, Japan.ORCID 0000-0002-2932-5904
Takanobu YamadaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Kanagawa, Japan.ORCID 0000-0003-3564-6891
Akihito TsujiDepartment of Clinical Oncology, Kagawa University Hospital, Kagawa, Japan.
Justin I OdegaardGuardant Health, Redwood City, California.ORCID 0000-0001-9957-2962
Hiroya TaniguchiDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.ORCID 0000-0003-1407-6682
Toshihiko DoiDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.ORCID 0000-0003-2042-6829
Satoshi FujiiDepartment of Molecular Pathology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.
Takayuki YoshinoDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
National Cancer Center Hospital East · JPKyushu University · JPAichi Cancer Center · JPChiba Cancer Center · JPGifu University · JPGuardant (United States) · USHokkaido University Hospital · JPJapanese Foundation For Cancer Research · JPJapan Society of Chemotherapy · JPKagawa University Hospital · JPKanagawa Prefectural Hospital Organization · JPKanazawa University · JPKansai Rosai Hospital · JPKobe City Medical Center General Hospital · JPKyorin University · JPNational Kyushu Medical Center · JPOsaka Medical and Pharmaceutical University · JPOsaka National Hospital · JPSaitama Cancer Center · JPShikoku Cancer Center · JP
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEXPERIMENTAL
designWe assessed genomic characteristics of
results
conclusionsctDNA sequencing identifies
Indexed as
Gene AmplificationCirculating Tumor DNAFemaleGenomeHumansMaleMiddle AgedNeoplasm StagingReceptor, Fibroblast Growth Factor, Type 2Retrospective StudiesStomach NeoplasmsCirculating Tumor DNAFGFR2 protein, humanReceptor, Fibroblast Growth Factor, Type 2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.